StockWatch
·

Akums Drugs and Pharmaceuticals Ltd

BSE: 544222

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
420.84
+0.6%+25.1%
Expenditure
377.00
+5.0%+23.5%
Net Profit
32.64
-27.2%+39.1%
OPM %
8.75%
-3.61pp+3.29pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00117.84235.67353.51471.35Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

CDMO Powers 32%, But Baddi Capex and Zambia Slip Narrow the Path

CDMO · volume growth · Baddi capex

Result verdictFollow-upQ2 FY2705 Nov 20266 minPharma & Healthcare

Strong CDMO, margins held; near-term capex & Zambia slip limit upside

CDMO volume growth · EBITDA expansion · Baddi capex ramp

TranscriptDeep diveQ2 FY2705 Nov 20266 minPharma & Healthcare

Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band

cdmo growth · margin expansion · pat surge

ResultsQ2 FY2702 Nov 20263 minPharma & Healthcare
Latest
Board Meeting2 Nov, 5:20 pm

Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band

Akums' consolidated Q2 FY27 (quarter ended 30 September 2026) revenue rose 31.9% YoY to ₹1,342.4 Cr and PAT surged 168.3% YoY to ₹114.6 Cr, with NPM expanding to 8.35% from 4.07% and OPM (EBITDA margin) to 14.51% from 9.28% a year ago — a straightforward YoY growth-cum-margin-expansion quarter, not a one-off: neither this quarter nor the year-ago quarter carried any exceptional item, so the 168% is a clean comparison. Sequentially the picture is milder — revenue +15.1% QoQ and PAT +13.5% QoQ — and OPM actually eased to 14.51% from Q1's 14.97%, so the QoQ print should be read as a continuation of an already-strong base rather than fresh acceleration; NPM similarly ticked down marginally QoQ (8.44%→8.35%). The margin story sits mainly in CDMO, the largest segment: external revenue grew 38.6% YoY to ₹1,114.9 Cr and segment result (post-depreciation) more than doubled to ₹259.0 Cr from ₹91.6 Cr, comfortably ahead of management's "high-teens volume growth" guidance from the Q1 FY27 call (value growth here is well above that bar, though volume is not separately disclosed). API, flagged for a monthly-EBITDA-breakeven target by end-FY27, narrowed its segment loss to -₹10.1 Cr from -₹18.4 Cr YoY — directionally on track — but the loss actually widened from Q1's -₹8.1 Cr, so the path isn't linear and bears watching. The reported 14.51% OPM sits inside management's reiterated 14–15% EBITDA margin target, meeting guidance, though it is off Q1's print which the company had flagged as running toward the "upper bracket." No public consensus estimate for this specific quarter turned up in a search of brokerage previews; the only available Street benchmark is a ~₹4,920 Cr FY27 full-year revenue consensus (+12.9%), against which Akums is tracking at ₹2,509 Cr for H1 FY27 — broadly consistent, not confirmable on PAT. On corporate developments, the quarter included Pure and Cure Healthcare's ₹56.0 Cr acquisition of Oriflame India's Roorkee and Noida manufacturing facilities, a stated capacity and color-cosmetics/skincare/wellness expansion move that is incremental to this quarter's P&L (deal completed during the quarter). A subsidiary separately received a ₹52.7 Cr NPPA demand notice in October, outside this result's numbers but a monitorable for the segment's liability position. Management's own press release framing — "PAT surges 168% YoY on margin expansion, revenue up 32%" — matches the reported figures without rounding discrepancies; no prior-quarter outlook from the company is contradicted by this print, and the cautiously-optimistic short-term tone from the August concall is borne out by the margin trajectory, even as Zambia's guided ~₹240 Cr H2 FY27 contribution is not yet separately visible in this segment breakout.

2 Nov 2026, 05:20 pm

Corporate Events

Board MeetingAKUMS
2026
2Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingAKUMS
2026
8Aug

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingAKUMS
2026
23Jul

Board Meeting

The Board Meeting was held on July 23, 2026, to consider and…

BSE Filing ↗
Board MeetingAKUMS
2026
10Jul

Board Meeting

The 22nd Annual General Meeting will be held to receive, con…

BSE Filing ↗
DividendAKUMS
2026
3Jul

₹3 / share

BSE Filing ↗
Board MeetingAKUMS
2024
9Nov

Board Meeting

Consider and approve the Un-audited (Standalone & Consolidat…

BSE Filing ↗
Board MeetingAKUMS
2024
24Aug

Board Meeting

Consider and approve the Un-audited (Standalone & Consolidat…

BSE Filing ↗